97 related articles for article (PubMed ID: 31128003)
21. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
23. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
25. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
[TBL] [Abstract][Full Text] [Related]
26. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.
Parkes A; Warneke CL; Clifton K; Al-Awadhi A; Oke O; Pestana RC; Alhalabi O; Litton JK; Hortobagyi GN
Oncologist; 2018 Nov; 23(11):1282-1288. PubMed ID: 30120166
[TBL] [Abstract][Full Text] [Related]
28. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
[TBL] [Abstract][Full Text] [Related]
29. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens AKM; Bos MEMM; Lopez-Yurda M; Bouma JM; Rademaker-Lakhai JM; Honkoop AH; de Graaf H; van Druten E; van Warmerdam LJC; van der Sangen MJC; Tjan-Heijnen VCG; Erdkamp FLG;
Breast Cancer Res Treat; 2018 Nov; 172(2):413-423. PubMed ID: 30121808
[TBL] [Abstract][Full Text] [Related]
30. Clinical analysis of patients with skeletal metastasis of lung cancer.
Cho YJ; Cho YM; Kim SH; Shin KH; Jung ST; Kim HS
BMC Cancer; 2019 Apr; 19(1):303. PubMed ID: 30943924
[TBL] [Abstract][Full Text] [Related]
31. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
32. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
33. Surgery of primary tumour has survival benefit in metastatic breast cancer with single-organ metastasis, especially bone.
Rhu J; Lee SK; Kil WH; Lee JE; Nam SJ
ANZ J Surg; 2015 Apr; 85(4):240-4. PubMed ID: 25996008
[TBL] [Abstract][Full Text] [Related]
34. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
Bishop AJ; Ensor J; Moulder SL; Shaitelman SF; Edson MA; Whitman GJ; Bishnoi S; Hoffman KE; Stauder MC; Valero V; Buchholz TA; Ueno NT; Babiera G; Woodward WA
Cancer; 2015 Dec; 121(24):4324-32. PubMed ID: 26348887
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
36. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
[TBL] [Abstract][Full Text] [Related]
39. [Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China].
Yang H; Wang SY; Ou W; Sun HB; Fang Q
Ai Zheng; 2009 Dec; 28(12):1310-6. PubMed ID: 19958627
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
